Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate in psoriatic arthritis.

M Cutolo1, B Seriolo, C Pizzorni

  • 1Research Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Genova, Italy. mcutolo@unige.it

Clinical and Experimental Rheumatology
|December 5, 2002
PubMed
Summary

Methotrexate (MTX) effectively treats severe psoriatic arthritis with positive outcomes. Low-dose MTX shows minimal liver and lung risks in PsA patients, though folic acid may reduce efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An engineered glove to follow finger function in rheumatoid arthritis: an observational prospective study.

Rheumatology international·2023
Same author

Emerging nailfold capillaroscopic patterns in COVID-19: from acute patients to survivors.

Reumatismo·2023
Same author

Nailfold capillaroscopy in the rheumatological current clinical practice in Italy: results of a national survey.

Reumatismo·2022
Same author

Body composition and bone status in relation to microvascular damage in systemic sclerosis patients.

Journal of endocrinological investigation·2020
Same author

Progression of nailfold capillaroscopic patterns and correlation with organ involvement in systemic sclerosis: a 12 year study.

Rheumatology (Oxford, England)·2020
Same author

Progression of nailfold capillaroscopic patterns and correlation with organ involvement in systemic sclerosis: a 12 year study.

Rheumatology (Oxford, England)·2019

Area of Science:

  • Rheumatology
  • Pharmacology

Background:

  • Methotrexate (MTX), a folic acid analogue, possesses antiproliferative and anti-inflammatory properties.
  • MTX is a widely adopted first-line therapy for severe, destructive psoriatic arthritis (PsA), demonstrating favorable clinical outcomes.
  • Concerns regarding MTX's safety profile, particularly hepatotoxicity and pulmonary toxicity, are critical in long-term PsA management.

Purpose of the Study:

  • To evaluate the safety and efficacy of methotrexate in managing psoriatic arthritis.
  • To assess the incidence of liver enzyme elevations and pulmonary fibrosis in PsA patients undergoing MTX treatment.
  • To investigate the impact of concomitant folic acid use on MTX efficacy and safety.

Main Methods:

  • Review of clinical data and studies on psoriatic arthritis patients treated with methotrexate.

Related Experiment Videos

  • Assessment of liver function tests and pulmonary function tests in patients receiving MTX.
  • Analysis of imaging techniques for detecting pulmonary changes.

    • Main Results:

    • Methotrexate demonstrates positive clinical results in severe psoriatic arthritis.
    • Significant liver changes and elevated serum enzymes are not a major concern in PsA patients on MTX.
    • Low-dose MTX treatment in PsA patients is not associated with pulmonary fibrosis, as confirmed by sensitive imaging and pulmonary function tests.

    Conclusions:

    • Methotrexate is a safe and effective treatment for severe psoriatic arthritis.
    • The risk of hepatotoxicity and pulmonary fibrosis is low with MTX therapy in PsA patients.
    • Concomitant folic acid use may reduce MTX efficacy by competing for folate receptors, necessitating careful consideration.